ImmunityBio
  • ANKTIVA®
  • Clinical Trials
    • Find a Trial
    • Become a Trial
      Investigator
    • License our Cells
  • Science
    • Platforms
    • Pipeline
    • Expanded Access
    • Research
  • Approach
    • Patients
    • Trial Investigators
    • Researchers
  • Condition
    • Bladder Cancer
    • Glioblastoma
    • HIV
    • Lynch / Colon Cancer
    • Non-Hodgkin Lymphoma
    • Human Papillomavirus
    • Non-Small Cell Lung Cancer
  • Company
    • About Us
    • Investors
    • News and Events
    • Contact
  • Careers
  • Founder’s Vision
    • Cancer Moonshot 2020
    • Childhood Cancer – Sen. McCain
    • Cancer Moonshot Announcement
    • Formation of ImmunityBio
Select Page

ANKTIVA Synergizes with T Cell Activity of BCG in Both the Naïve and Unresponsive Setting by Activating NK Cells, Interferon Gamma, and Driving Memory CD8+ Killer T Cells

May 2, 2024 | Bladder Cancer

IL-15 Superagonist NAI in BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer

IL-15 Superagonist NAI in BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer

Jun 29, 2023 | Bladder Cancer

Recent Posts

  • ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock
  • JPM Healthcare Conference
  • ASCO GI
  • ASCO GU
  • ImmunityBio Completes ANKTIVA’s Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months
 

Quicklinks

  • Pipeline
  • Careers
  • News and Events
  • Investors
  • Contact

Follow Us

  •  Facebook
  •  X
  •  LinkedIn

Legal

  • Privacy Policy
  • Legal Notice
  • Patent Notice
  • How-To-Use-Accessibe

© 2024 ImmunityBio, Inc. All Rights Reserved.

A member of the NantWorks ecosystem of companies

’ImmunityBio’, ‘ImmunityBio Care’, 'Anktiva’, ‘ThAnktiva’, ‘haNK’, ‘taNK’, ‘ceNK’, ‘NK-92’, ‘Nant Cancer Vaccine’, ‘NANT 001’, ‘NANT XL’, ‘NANT 001 and Design’, ‘QUILT’, ‘Outsmart Your Disease’, ‘Smart Therapies for Difficult Diseases’, ‘Nantkwest’, ‘VivaBioCell’, and ‘Infacell’ are trademarks or registered trademarks of ImmunityBio, Inc., its subsidiaries and affiliates.

The Natural Killer Cell platform consists of investigational agents that are restricted by federal law to investigational use only.

The Natural Killer Cell platform is being investigated in multiple clinical trials across tumor sites.

The content of this website is protected by Title 17 of the U.S. Code and may not be reproduced in whole or in part by any means.

Sitemap